Terms: = Prostate cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Treatment
442 results:
1. Inhibition of prostate cancer Cell Survival and Proliferation by Carnosic Acid Is Associated with Inhibition of Akt and Activation of AMPK Signaling.
Nadile M; Sze NSK; Fajardo VA; Tsiani E
Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732504
[TBL] [Abstract] [Full Text] [Related]
2. Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
[TBL] [Abstract] [Full Text] [Related]
3. The interplay between autophagy and ferroptosis presents a novel conceptual therapeutic framework for neuroendocrine prostate cancer.
Wang Y; Wu N; Li J; Liang J; Zhou D; Cao Q; Li X; Jiang N
Pharmacol Res; 2024 May; 203():107162. PubMed ID: 38554788
[TBL] [Abstract] [Full Text] [Related]
4. Scutellarin, a flavonoid compound from Scutellaria barbata, suppresses growth of breast cancer stem cells in vitro and in tumor-bearing mice.
Ma H; Yue GG; Lee JK; Gao S; Yuen KK; Cheng W; Li X; Lau CB
Phytomedicine; 2024 Jun; 128():155418. PubMed ID: 38518647
[TBL] [Abstract] [Full Text] [Related]
5. New penta-Coordinated Cadmium(II) Complexes: Synthesis, Characterization, Thermal, Antimicrobial, Antioxidant and Cytotoxicity Properties.
Nejadmirfathi M; Montazerozohori M; Naghiha R; Panahi Kokhdan E
Chem Biodivers; 2024 May; 21(5):e202301667. PubMed ID: 38502834
[TBL] [Abstract] [Full Text] [Related]
6. Curcumin Enhances the Anti-cancer Efficacy of CDK4/6 Inhibitors in prostate cancer.
Zhao H; Ding R; Han J
Arch Esp Urol; 2024 Jan; 77(1):57-66. PubMed ID: 38374014
[TBL] [Abstract] [Full Text] [Related]
7. Idebenone Exerts anti-Triple Negative Breast cancer Effects via Dual Signaling Pathways of GADD45 and AMPK.
Zhang Y; Yang F; Wu J; Huang J; Li P; Huang G
Nutr Cancer; 2024; 76(4):379-392. PubMed ID: 38332562
[TBL] [Abstract] [Full Text] [Related]
8. Leptin promotes proliferation of human undifferentiated spermatogonia by activating the PI3K/AKT/mtor pathway.
Xin S; Xiaoxuan L; Yixuan Z; Zhikang C
Am J Reprod Immunol; 2024 Jan; 91(1):e13811. PubMed ID: 38282611
[TBL] [Abstract] [Full Text] [Related]
9. Dual targeting of the androgen receptor and PI3K/AKT/mtor pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
Sugawara T; Nevedomskaya E; Heller S; Böhme A; Lesche R; von Ahsen O; Grünewald S; Nguyen HM; Corey E; Baumgart SJ; Georgi V; Pütter V; Fernández-Montalván A; Vasta JD; Robers MB; Politz O; Mumberg D; Haendler B
Mol Oncol; 2024 Mar; 18(3):726-742. PubMed ID: 38225213
[TBL] [Abstract] [Full Text] [Related]
10. Phase I Study of mtorC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mtor/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract] [Full Text] [Related]
11. VWCE modulates amino acid-dependent mtor signaling and coordinates with KICSTOR to recruit GATOR1 to the lysosomes.
Zhao T; Guan Y; Xu C; Wang D; Guan J; Liu Y
Nat Commun; 2023 Dec; 14(1):8464. PubMed ID: 38123554
[TBL] [Abstract] [Full Text] [Related]
12.
Giordano F; Comità S; Venneri G; Rago V; Naimo GD; De Amicis F; De Bartolo A; Tundis R; Mauro L; Panno ML
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003541
[TBL] [Abstract] [Full Text] [Related]
13. Auraptene Enhances AMP-Activated Protein Kinase Phosphorylation and Thereby Inhibits the Proliferation, Migration and Expression of Androgen Receptors and prostate-Specific Antigens in prostate cancer Cells.
Akasaka Y; Hasei S; Ohata Y; Kanna M; Nakatsu Y; Sakoda H; Fujishiro M; Kushiyama A; Ono H; Matsubara A; Hinata N; Asano T; Yamamotoya T
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958994
[No Abstract] [Full Text] [Related]
14. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
15. Total flavonoids of Litchi chinensis Sonn. seed inhibit prostate cancer growth in bone by regulating the bone microenvironment via inactivation of the HGFR/NF-κB signaling pathway.
Zhang W; Chen T; Yang P; Li X; Zhu D; Su Z; Yang X; Jin R; Lan T; Guo H
J Ethnopharmacol; 2024 Jan; 319(Pt 3):117327. PubMed ID: 37871755
[TBL] [Abstract] [Full Text] [Related]
16. Exploring the role of PI3K/AKT/mtor inhibitors in hormone-related cancers: A focus on breast and prostate cancer.
Wylaź M; Kaczmarska A; Pajor D; Hryniewicki M; Gil D; Dulińska-Litewka J
Biomed Pharmacother; 2023 Dec; 168():115676. PubMed ID: 37832401
[TBL] [Abstract] [Full Text] [Related]
17. Sennoside A induces autophagic death of prostate cancer via inactivation of PI3K/AKT/mtor axis.
Qiao S; Zhang W; Jiang Y; Su Y
J Mol Histol; 2023 Dec; 54(6):645-654. PubMed ID: 37740843
[TBL] [Abstract] [Full Text] [Related]
18. The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy.
Ali A; Mekhaeil B; Biziotis OD; Tsakiridis EE; Ahmadi E; Wu J; Wang S; Singh K; Menjolian G; Farrell T; Mesci A; Liu S; Berg T; Bramson JL; Steinberg GR; Tsakiridis T
Commun Biol; 2023 Sep; 6(1):919. PubMed ID: 37684337
[TBL] [Abstract] [Full Text] [Related]
19. Exosomal miR-222-3p contributes to castration-resistant prostate cancer by activating mtor signaling.
Wang W; Kong P; Feng K; Liu C; Gong X; Sun T; Duan X; Sang Y; Jiang Y; Li X; Zhang L; Tao Z; Liu W
Cancer Sci; 2023 Nov; 114(11):4252-4269. PubMed ID: 37671589
[TBL] [Abstract] [Full Text] [Related]
20. Targeted inhibition of mtor by BML-275 induces mitochondrial-mediated apoptosis and autophagy in prostate cancer.
Li W; Li D; Ma Q; Chen Y; Hu Z; Bai Y; Xie L
Eur J Pharmacol; 2023 Oct; 957():176035. PubMed ID: 37657741
[TBL] [Abstract] [Full Text] [Related]
[Next]
